TCF7L2 Antibody - #DF7622

(2)   (4)  
Product: TCF7L2 Antibody
Catalog: DF7622
Description: Rabbit polyclonal antibody to TCF7L2
Application: WB
Reactivity: Human, Mouse, Rat, Monkey
Prediction: Pig, Zebrafish, Horse, Sheep, Xenopus
Mol.Wt.: 68 kDa, 50 kDa; 68kD(Calculated).
Uniprot: Q9NQB0
RRID: AB_2841109

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:1000-3000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat,Monkey
Prediction:
Pig(100%), Zebrafish(100%), Horse(100%), Sheep(100%), Xenopus(100%)
Clonality:
Polyclonal
Specificity:
TCF7L2 Antibody detects endogenous levels of total TCF7L2.
RRID:
AB_2841109
Cite Format: Affinity Biosciences Cat# DF7622, RRID:AB_2841109.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

HMG box transcription factor 4; hTCF 4; hTCF-4; T cell factor 4; T cell specific HMG box; T cell specific transcription factor 4; T-cell factor 4; T-cell-specific transcription factor 4; TCF 4; TCF-4; TCF4; TCF7L2; TCF7L2 protein; TF7L2_HUMAN; Transcription factor 7 like 2; Transcription factor 7 like 2 T cell specific HMG box; Transcription factor 7-like 2;

Immunogens

Immunogen:
Uniprot:

Q9NQB0(TF7L2_HUMAN) >>Visit HPA database.

Gene(ID):
TCF7L2(6934)
Expression:
Q9NQB0 TF7L2_HUMAN:

Detected in epithelium from small intestine, with the highest expression at the top of the crypts and a gradient of expression from crypt to villus. Detected in colon epithelium and colon cancer, and in epithelium from mammary gland and carcinomas derived therefrom.

Sequence:
MPQLNGGGGDDLGANDELISFKDEGEQEEKSSENSSAERDLADVKSSLVNESETNQNSSSDSEAERRPPPRSESFRDKSRESLEEAAKRQDGGLFKGPPYPGYPFIMIPDLTSPYLPNGSLSPTARTLHFQSGSTHYSAYKTIEHQIAVQYLQMKWPLLDVQAGSLQSRQALKDARSPSPAHIVSNKVPVVQHPHHVHPLTPLITYSNEHFTPGNPPPHLPADVDPKTGIPRPPHPPDISPYYPLSPGTVGQIPHPLGWLVPQQGQPVYPITTGGFRHPYPTALTVNASMSRFPPHMVPPHHTLHTTGIPHPAIVTPTVKQESSQSDVGSLHSSKHQDSKKEEEKKKPHIKKPLNAFMLYMKEMRAKVVAECTLKESAAINQILGRRWHALSREEQAKYYELARKERQLHMQLYPGWSARDNYGKKKKRKRDKQPGETNEHSECFLNPCLSLPPITDLSAPKKCRARFGLDQQNNWCGPCRRKKKCVRYIQGEGSCLSPPSSDGSLLDSPPPSPNLLGSPPRDAKSQTEQTQPLSLSLKPDPLAHLSMMPPPPALLLAEATHKASALCPNGALDLPPAALQPAAPSSSIAQPSTSSLHSHSSLAGTQPQPLSLVTKSLE

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Sheep
100
Xenopus
100
Zebrafish
100
Bovine
0
Dog
0
Chicken
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q9NQB0 As Substrate

Site PTM Type Enzyme
K22 Sumoylation
S35 Phosphorylation
S58 Phosphorylation
S59 Phosphorylation
S60 Phosphorylation
S74 Phosphorylation
S79 Phosphorylation
S82 Phosphorylation
K88 Ubiquitination
R126 Methylation
Y151 Phosphorylation
K173 Acetylation
S177 Phosphorylation Q9UKE5 (TNIK)
S179 Phosphorylation
T201 Phosphorylation Q9UBE8 (NLK)
T212 Phosphorylation Q9UBE8 (NLK)
S324 Phosphorylation
K335 Ubiquitination
K352 Ubiquitination
K362 Acetylation
K362 Ubiquitination
K367 Acetylation
K398 Ubiquitination
Y399 Phosphorylation
Y400 Phosphorylation
Y414 Phosphorylation
S418 Phosphorylation
Y489 Phosphorylation
K563 Acetylation

Research Backgrounds

Function:

Participates in the Wnt signaling pathway and modulates MYC expression by binding to its promoter in a sequence-specific manner. Acts as repressor in the absence of CTNNB1, and as activator in its presence. Activates transcription from promoters with several copies of the Tcf motif 5'-CCTTTGATC-3' in the presence of CTNNB1. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by TCF7L2/TCF4 and CTNNB1. Expression of dominant-negative mutants results in cell-cycle arrest in G1. Necessary for the maintenance of the epithelial stem-cell compartment of the small intestine.

PTMs:

In vitro, phosphorylated by TNIK.

Phosphorylated at Thr-201 and/or Thr-212 by NLK. Phosphorylation by NLK at these sites inhibits DNA-binding by TCF7L2/TCF4, thereby preventing transcriptional activation of target genes of the canonical Wnt/beta-catenin signaling pathway.

Polysumoylated. Sumoylation is enhanced by PIAS family members and desumoylation is enhanced by SENP2. Sumoylation/desumoylation regulates TCF7L2/TCF4 transcription activity in the Wnt/beta-catenin signaling pathway without altering interaction with CTNNB1 nor binding to DNA.

Subcellular Location:

Nucleus>PML body.
Note: Diffuse pattern. Colocalizes with SUMO1 and PIAS4 in a subset of PML (promyelocytic leukemia) nuclear bodies.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Detected in epithelium from small intestine, with the highest expression at the top of the crypts and a gradient of expression from crypt to villus. Detected in colon epithelium and colon cancer, and in epithelium from mammary gland and carcinomas derived therefrom.

Subunit Structure:

Interacts with TGFB1I1 (By similarity). Interacts with CTNNB1 (via the armadillo repeat); forms stable transcription complex. Interacts with EP300. Interacts with NLK. Interacts with CCDC85B (probably through the HMG box); prevents interaction with CTNNB1. Interacts with TNIK. Interacts with MAD2L2; prevents TCF7L2/TCF4 binding to promZIPK/DAPK3oters, negatively modulating its transcriptional activity. Interacts with ZIPK/DAPK3. Interacts with XIAP/BIRC4 and TLE3. Interacts with DDIT3/CHOP. The CTNNB1 and TCF7L2/TCF4 complex interacts with PML (isoform PML-4). Identified in a complex with CTNNB1 and FERMT2. Interacts with SPIN1. Interacts with C11orf84/SPINDOC in a SPIN1-dependent manner.

Family&Domains:

The promoter-specific activation domain interacts with the transcriptional coactivator EP300.

Belongs to the TCF/LEF family.

Research Fields

· Cellular Processes > Cellular community - eukaryotes > Adherens junction.   (View pathway)

· Environmental Information Processing > Signal transduction > Wnt signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Hippo signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Colorectal cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Endometrial cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Thyroid cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Basal cell carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Acute myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

· Human Diseases > Cardiovascular diseases > Arrhythmogenic right ventricular cardiomyopathy (ARVC).

· Organismal Systems > Endocrine system > Melanogenesis.

References

1). NOX4 stimulates ANF secretion via activation of the Sirt1/Nrf2/ATF3/4 axis in hypoxic beating rat atria. Molecular Medicine Reports (PubMed: 35029280) [IF=3.4]

Application: WB    Species: rat    Sample: atria

Figure 5.| Effect of nuclear factor erythroid‑2‑related factor 2 inhibitor on TCF3, TCF4 and LEF1 protein expression induced by hypoxia in beating rat atria.(A)Representative western blots.

Application: WB    Species: Rat    Sample: atria

Figure 5. Effect of nuclear factor erythroid-2-related factor 2 inhibitor on TCF3, TCF4 and LEF1 protein expression induced by hypoxia in beating rat atria. (A) Representative western blots. (B) Quantification of protein expression levels. (C) LEF1 protein expression was detected using immunofluorescence staining (scale bar, 100 µm). Data are presented as the mean ± SE. n=5. ***P<0.001 vs. control; ###P<0.001 vs. hypoxia. TCF, T-cell factor; LEF1, lymphoid enhancer factor 1; cont, control; hy, hypoxia; ML, ML385.
2). Src-IL-18 signaling regulates the secretion of atrial natriuretic factor in hypoxic beating rat atria. Kardiologia Polska (PubMed: 34176112) [IF=3.3]

Application: WB    Species: rat    Sample: atria

Figure 4. | A, B. Effect of IL-18 on the protein levels of ATF3, TCF3, TCF4 and LEF1.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.